Iovance Biotherapeutics Faces Class Action Lawsuit
Pomerantz LLP has announced a class action lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) that has attracted attention from investors concerned over recent developments. This legal action focuses on whether the company and select officers or directors have engaged in practices that constitute securities fraud or unlawful business conduct.
Investors Urged to Act Quickly
Shareholders who acquired Iovance securities during the designated class period are encouraged to reach out to Pomerantz LLP. Those interested in participating must act before the deadline for appointing a Lead Plaintiff, which is set at July 14, 2025. If you want to inquire, contact Danielle Peyton at 646-581-9980 or via email at dpeyton@pomlaw.com.
Understanding the Lawsuit
This class action emerges in light of Iovance's recent financial struggles, particularly following a significant decline in revenue projections and stock performance. Investors need to understand the implications of this lawsuit which may impact their financial decisions regarding their holdings in Iovance.
Recent Financial Performance Report
In an unexpected market announcement on May 8, 2025, Iovance disclosed its first quarter financials, indicating total product revenue of $49.3 million. This figure represents a noticeable drop from the previous quarter's revenue of $73.7 million. Further complicating matters, the company has revised its full fiscal year guidance down from a range of $450 million - $475 million to a new estimate of $250 million - $300 million. This adjustment reflects changes in launch dynamics for its lead product candidate, Amtagvi, and acknowledges the anticipated trajectories for authorized treatment centers.
Impact on Stock Prices
The fallout from this announcement was immediate; Iovance's stock price plummeted by $1.42 per share, amounting to a staggering 44.79% decrease and closing at $1.75 per share the very next day, May 9, 2025. Such fluctuations in stock price resonate deeply with investors.
About Pomerantz LLP
Pomerantz LLP is recognized widely as a premier law firm specializing in corporate and securities class action litigation. Established over 85 years ago by Abraham L. Pomerantz, the firm has a legacy of advocating for those victimized by securities fraud and corporate misconduct. Their commitment to fighting for investors' rights has led to substantial recoveries in previous cases, thus highlighting their capability.
Contact Information for Investors
Investors looking to join the class action or requiring more information can contact Pomerantz LLP. They have offices in major cities including New York, Chicago, and Los Angeles and are equipped to deal with queries regarding participation in the lawsuit.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit addresses potential securities fraud or unlawful business practices by Iovance Biotherapeutics and certain executives.
How can I find out more about joining the lawsuit?
Interested individuals can reach out to Danielle Peyton at Pomerantz LLP either by phone or email for more information on participating.
What recent financial changes led to the lawsuit?
Iovance recently revised its revenue projections drastically, which prompted concerns among investors and consequently led to the class action lawsuit.
What is the deadline for filing?
The deadline to request to be appointed as a Lead Plaintiff in the class action is July 14, 2025.
Can any Iovance investor join the lawsuit?
Yes, any investor who purchased or acquired Iovance securities during the class period can potentially join the lawsuit.
